Therefore, the T2DM medication empagliflozin, a sodium glucose cotransporter‐2 (SGLT2) inhibitor, is currently investigated for its potential to improve outcomes for comorbidities, for example, in the EmDia study, a randomized, double‐blind, and placebo‐controlled clinical study, aiming to evaluate the short‐term effects of empagliflozin on left ventricular diastolic function [5]. Here, SLC5A2 is linked to type 2 diabetes mellitus.